AstraZeneca: positive trial in cardiac amyloidosis -February 02, 2024 at 06:54 am EST

AstraZeneca announces that the results of a Phase III trial conducted in Japan with acoramide in adult patients with transthyretin cardiac amyloidosis are consistent with those of the global Phase...

Related Keywords

Japan ,Japanese ,Marc Dunoyer ,Yukio Ando ,Bio Pharma ,Astrazeneca ,Amyloidosis Research ,Nagasaki International University ,Markets ,